Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.

British journal of haematology - 1 Jul 2021

Ware Russell E, Dertinger Stephen D

Abstract excerpt

Hydroxyurea (hydroxycarbamide) is approved for treating both children and adults with sickle cell anaemia (SCA). Fetal haemoglobin (HbF) induction is the primary treatment response, along with improved anaemia, reduced haemolysis, myelosuppression and decreased endothelial inflammation. Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to DNA Damage
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Mutation

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 33570176
DOI: 10.1111/bjh.17323

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.PMID 33570176Read ↗

Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.Semantic proximity Read ↗

Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell diseaseSemantic proximity Read ↗

Mutagenic and Genotoxic Effect of HydroxyureaSemantic proximity Read ↗

The Cell Killing Mechanisms of HydroxyureaSemantic proximity Read ↗

DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyureaSemantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Simultaneous adjunctive treatment of malaria and its co-evolved genetic disorder sickle cell anaemiaSemantic proximity Read ↗

Hydroxyurea (hydroxycarbamide) for sickle cell disease.Semantic proximity Read ↗

Genotoxic aldehydes in the hematopoietic systemSemantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

The paradox of HbSC disease-Not so benign after all.Semantic proximity Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.